Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm

Ania Kielar; Kathryn J. Fowler; Sara Lewis; Vahid Yaghmai; Frank H. Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K. Do

doi:10.1007/s00261-017-1281-6

Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm

Ania Kielar, Kathryn J. Fowler, Sara Lewis, Vahid Yaghmai, Frank H. Miller, Hooman Yarmohammadi, Charles Kim, Victoria Chernyak, Takeshi Yokoo, Jeffrey Meyer, Isabel Newton, Richard K. Do^*

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Radiologists play a central role in the assessment of patient response to locoregional therapies for hepatocellular carcinoma (HCC). The identification of viable tumor following treatment guides further management and potentially affects transplantation eligibility. Liver Imaging Reporting and Data Systems (LI-RADS) first introduced the concept of LR-treated in 2014, and a new treatment response algorithm is included in the 2017 update to assist radiologists in image interpretation of HCC after locoregional therapy. In addition to offering imaging criteria for viable and nonviable HCC, new concepts of nonevaluable tumors as well as tumors with equivocal viability are introduced. Existing guidelines provided by response evaluation criteria in solid tumors (RECIST) and modified RECIST address patient-level assessments and are routinely used in clinical trials but do not address the variable appearances following different locoregional therapies. The new LI-RADS treatment response algorithm addresses this gap and offers a comprehensive approach to assess treatment response for individual lesions after a variety of locoregional therapies, using either contrast-enhanced CT or MRI.

Original language	English (US)
Pages (from-to)	218-230
Number of pages	13
Journal	Abdominal Radiology
Volume	43
Issue number	1
DOIs	https://doi.org/10.1007/s00261-017-1281-6
State	Published - Jan 1 2018

Funding

Funding Ania Kielar was funded by General Electric. Richard K Do received support from the NIH/NCI Cancer Center Support Grant P30 CA008748.

Keywords

Hepatocellular carcinoma
LI-RADS
Locoregional therapy
RECIST
Response

ASJC Scopus subject areas

Gastroenterology
Urology
Radiological and Ultrasound Technology
Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00261-017-1281-6

Cite this

@article{e31149522e7447a89f1e5bb1a4939433,

title = "Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm",

abstract = "Radiologists play a central role in the assessment of patient response to locoregional therapies for hepatocellular carcinoma (HCC). The identification of viable tumor following treatment guides further management and potentially affects transplantation eligibility. Liver Imaging Reporting and Data Systems (LI-RADS) first introduced the concept of LR-treated in 2014, and a new treatment response algorithm is included in the 2017 update to assist radiologists in image interpretation of HCC after locoregional therapy. In addition to offering imaging criteria for viable and nonviable HCC, new concepts of nonevaluable tumors as well as tumors with equivocal viability are introduced. Existing guidelines provided by response evaluation criteria in solid tumors (RECIST) and modified RECIST address patient-level assessments and are routinely used in clinical trials but do not address the variable appearances following different locoregional therapies. The new LI-RADS treatment response algorithm addresses this gap and offers a comprehensive approach to assess treatment response for individual lesions after a variety of locoregional therapies, using either contrast-enhanced CT or MRI.",

keywords = "Hepatocellular carcinoma, LI-RADS, Locoregional therapy, RECIST, Response",

author = "Ania Kielar and Fowler, {Kathryn J.} and Sara Lewis and Vahid Yaghmai and Miller, {Frank H.} and Hooman Yarmohammadi and Charles Kim and Victoria Chernyak and Takeshi Yokoo and Jeffrey Meyer and Isabel Newton and Do, {Richard K.}",

note = "Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media, LLC.",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s00261-017-1281-6",

language = "English (US)",

volume = "43",

pages = "218--230",

journal = "Abdominal Radiology",

issn = "2366-004X",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm

AU - Kielar, Ania

AU - Fowler, Kathryn J.

AU - Lewis, Sara

AU - Yaghmai, Vahid

AU - Miller, Frank H.

AU - Yarmohammadi, Hooman

AU - Kim, Charles

AU - Chernyak, Victoria

AU - Yokoo, Takeshi

AU - Meyer, Jeffrey

AU - Newton, Isabel

AU - Do, Richard K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Radiologists play a central role in the assessment of patient response to locoregional therapies for hepatocellular carcinoma (HCC). The identification of viable tumor following treatment guides further management and potentially affects transplantation eligibility. Liver Imaging Reporting and Data Systems (LI-RADS) first introduced the concept of LR-treated in 2014, and a new treatment response algorithm is included in the 2017 update to assist radiologists in image interpretation of HCC after locoregional therapy. In addition to offering imaging criteria for viable and nonviable HCC, new concepts of nonevaluable tumors as well as tumors with equivocal viability are introduced. Existing guidelines provided by response evaluation criteria in solid tumors (RECIST) and modified RECIST address patient-level assessments and are routinely used in clinical trials but do not address the variable appearances following different locoregional therapies. The new LI-RADS treatment response algorithm addresses this gap and offers a comprehensive approach to assess treatment response for individual lesions after a variety of locoregional therapies, using either contrast-enhanced CT or MRI.

AB - Radiologists play a central role in the assessment of patient response to locoregional therapies for hepatocellular carcinoma (HCC). The identification of viable tumor following treatment guides further management and potentially affects transplantation eligibility. Liver Imaging Reporting and Data Systems (LI-RADS) first introduced the concept of LR-treated in 2014, and a new treatment response algorithm is included in the 2017 update to assist radiologists in image interpretation of HCC after locoregional therapy. In addition to offering imaging criteria for viable and nonviable HCC, new concepts of nonevaluable tumors as well as tumors with equivocal viability are introduced. Existing guidelines provided by response evaluation criteria in solid tumors (RECIST) and modified RECIST address patient-level assessments and are routinely used in clinical trials but do not address the variable appearances following different locoregional therapies. The new LI-RADS treatment response algorithm addresses this gap and offers a comprehensive approach to assess treatment response for individual lesions after a variety of locoregional therapies, using either contrast-enhanced CT or MRI.

KW - Hepatocellular carcinoma

KW - LI-RADS

KW - Locoregional therapy

KW - RECIST

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=85026834463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026834463&partnerID=8YFLogxK

U2 - 10.1007/s00261-017-1281-6

DO - 10.1007/s00261-017-1281-6

M3 - Article

C2 - 28780679

AN - SCOPUS:85026834463

SN - 2366-004X

VL - 43

SP - 218

EP - 230

JO - Abdominal Radiology

JF - Abdominal Radiology

IS - 1

ER -

Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this